Enanta Pharmaceuticals

Health biotech drug development research

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta’s research and development is currently focused on three disease targets: Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH)/PBC and Respiratory Syncytial Virus (RSV).

Revenue(FY, 2017)

$102.8 M

Market capitalization(2018-06-14)

$2.1 B

Type

Public

Watertown, US

Founded

1998

Size (employees)

89 (est)+18%

Website

enanta.com

Enanta Pharmaceuticals was founded in 1998 and is headquartered in Watertown, US

Report incorrect company information

Key People/Management at Enanta Pharmaceuticals

Jay R. Luly

President, Chief Executive Officer and Director

Yat Sun Or

Senior Vice President, Research & Development and Chief Scientific Officer

Paul J. Mellett

Senior Vice President, Finance & Administration and Chief Financial Officer

Report incorrect company information

Enanta Pharmaceuticals Office Locations

Enanta Pharmaceuticals has an office in Watertown

Watertown, US (HQ)

500 Arsenal Street

Show all (1)

Report incorrect company information

Enanta Pharmaceuticals Financials and Metrics

Enanta Pharmaceuticals Financials

Enanta Pharmaceuticals's revenue was reported to be $102.81 m in FY, 2017

Summary

USD
Revenue (Q2, 2018)	82.2 m
Net income (Q2, 2018)	24.2 m
EBIT (Q2, 2018)	31.2 m
Market capitalization (14-Jun-2018)	2.1 b
Closing share price (14-Jun-2018)	111
Cash (31-Mar-2018)	66.9 m

Enanta Pharmaceuticals's current market capitalization is $2.1 b.

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Revenue	32.1 m	47.7 m	160.9 m	88.3 m	102.8 m
Revenue growth, %		49%	237%	(45%)
General and administrative expense				17 m	20.7 m
R&D expense				40.5 m	57.5 m

Quarterly

USD	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q2, 2018
Revenue	42.1 m	77.5 m	57.4 m	11.6 m	48.4 m	13 m	14 m	10.4 m	9 m	82.2 m
General and administrative expense	2.6 m	2.8 m	3.4 m	3.6 m	3.8 m	4.4 m	4.3 m	4.9 m	5.5 m	11.5 m
R&D expense	4.6 m	4.5 m	5.4 m	6.3 m	9 m	9.1 m	10.8 m	12.5 m	13 m	39.4 m
Operating expense total	7.2 m	7.3 m	8.8 m	9.9 m	12.9 m	13.6 m	15.1 m	17.5 m	18.5 m	50.9 m

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	8.9 m	30.7 m	21.7 m	16.6 m	65.7 m
Accounts Receivable	808 k	1.7 m	15.3 m	12.8 m	10.6 m
Inventories	1.6 m	1.6 m	8.3 m	9.2 m	3.5 m
Current Assets	104.7 m	108 m	170.6 m	232.2 m	237.8 m

Quarterly

USD	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q2, 2018
Cash	26.4 m	34.1 m	25.8 m	19.8 m	46.2 m	56.4 m	24.8 m	20.6 m	19.2 m	66.9 m
Accounts Receivable	399 k	76.6 m	7.1 m	11.7 m	17.9 m	13 m	14 m	10.4 m	9 m	44 m
Current Assets	111.7 m	185.1 m	177.8 m	172.6 m	209 m	242.7 m	241.8 m	224.1 m	190.6 m	305.7 m
PP&E	1.6 m	1.9 m	2.3 m	2.6 m	7.9 m	7.7 m	7.5 m	8.3 m	8.5 m	8.6 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	9.6 m	34.4 m	79 m	21.7 m	17.7 m
Depreciation and Amortization	221 k	352 k	639 k	1.7 m	2.1 m
Inventories	(307 k)	568 k	(6.7 m)	(964 k)	3.5 m
Accounts Payable	115 k	399 k	(543 k)	1.5 m	633 k

Quarterly

USD	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q2, 2018
Net Income	39.5 m	42 m	70.8 m	73.2 m	26.2 m	24.5 m	23.5 m	(5 m)	(10.4 m)	24.2 m
Depreciation and Amortization	242 k	129 k	270 k	435 k	339 k	772 k	1.2 m	493 k	1 m	1.2 m
Accounts Payable	(190 k)	(1.3 m)	488 k	(332 k)	149 k	1.2 m	677 k	(1.3 m)	688 k	565 k
Cash From Operating Activities	25.1 m	(5.6 m)	93.3 m	79 m	30 m	40 m	37.9 m	3.1 m	143 k	(3.2 m)